Literature DB >> 9619025

[Estimated prevalence rate of HTLV-I uveitis in Chikugo].

E Ikeda1, A Ono, N Hikita, K Arima, M Mochizuki, K Yamaguchi, K Tajima, H Kiyokawa.   

Abstract

To estimate the prevalence rate of human T-cell lymphotropic virus type 1 (HTLV-I) uveitis, an epidemiological survey was carried out in the Chikugo District of Fukuoka Prefecture between 1 September and 31 October 1995. The survey was done by sending questionnaires on uveitis patients to all ophthalmological institutes in the district and measuring the serum antibody to HTLV-I. The recovery rate of the survey was 39 of 48 institutes (81.3%). A total of 357 patients with uveitis were reported in the survey, of whom 317 (88.8%) were tested for their seropositivity to HTLV-I. Among them, 18 patients were counted as having HTLV-I uveitis (HU) on 1 October 1995. Based on these data together with the age- and sex-specific population of HTLV-I carriers in the Chikugo District, it was estimated that the crude prevalence rates of HU per 100,000 HTLV-I carrier population were 58.6 in males, 152.0 in females, and 112.2 in both sexes. The prevalence rate of HU was slightly higher than that of HTLV-I associated myelopathy.

Entities:  

Mesh:

Year:  1998        PMID: 9619025

Source DB:  PubMed          Journal:  Nippon Ganka Gakkai Zasshi        ISSN: 0029-0203


  2 in total

1.  Real-world clinical course of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Japan.

Authors:  Shuntaro Tsutsumi; Tomoo Sato; Naoko Yagishita; Junji Yamauchi; Natsumi Araya; Daisuke Hasegawa; Misako Nagasaka; Ariella L G Coler-Reilly; Eisuke Inoue; Ayako Takata; Yoshihisa Yamano
Journal:  Orphanet J Rare Dis       Date:  2019-10-21       Impact factor: 4.123

Review 2.  Updates on HTLV-1 Uveitis.

Authors:  Koju Kamoi; Toshiki Watanabe; Kaoru Uchimaru; Akihiko Okayama; Seiko Kato; Toyotaka Kawamata; Hisako Kurozumi-Karube; Noe Horiguchi; Yuan Zong; Yoshihisa Yamano; Isao Hamaguchi; Yasuhito Nannya; Arinobu Tojo; Kyoko Ohno-Matsui
Journal:  Viruses       Date:  2022-04-12       Impact factor: 5.818

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.